Thomas Lingelbach, Valneva CEO
June 21, 2022 07:16 AM EDT
Financing
Deals

Pfiz­er nabs $95M stake in Val­ne­va as Ly­me dis­ease vac­cine ap­proach­es piv­otal study

Max Gelman

Senior Editor

Pfiz­er is in­vest­ing some mon­ey in its Ly­me dis­ease part­ner biotech as the pair gears up for a Phase III study.

The Big Phar­ma chipped …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times